Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Phase 3

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: R-CHOP
Drug: Rituximab
Drug: R-CHOP / R-HAD
Drug: Lenalidomide

First Posted Date: 2013-05-30

Last Posted Date: 2023-12-05

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 623

Registration Number: NCT01865110

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇩🇪
Klinikum Nürnberg, Nürnberg, Germany
🇩🇪
Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany

and more 137 locations

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Other: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-05-29

Last Posted Date: 2024-11-28

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 1087

Registration Number: NCT01863550

Locations: 🇺🇸
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States

and more 913 locations

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2013-05-17

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 349

Registration Number: NCT01856192

Locations: 🇺🇸
Ottumwa Regional Health Center, Ottumwa, Iowa, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States
🇺🇸
MercyOne Waterloo Cancer Center, Waterloo, Iowa, United States

and more 502 locations

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Ixazomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2013-05-09

Last Posted Date: 2023-07-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 705

Registration Number: NCT01850524

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Drug: idelalisib

First Posted Date: 2013-04-24

Last Posted Date: 2018-01-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 106

Registration Number: NCT01838434

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 1 locations

Lenalidomide Plus Rituximab (R) in Non Follicular NHL

Phase 2

Conditions: Indolent Non Hodgkin Lymphoma

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-04-12

Last Posted Date: 2013-04-12

Lead Sponsor: Gruppo Italiano Studio Linfomi

Target Recruit Count: 44

Registration Number: NCT01830478

Locations: 🇮🇹
Centro Oncologico Modenese, Modena, MO, Italy

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2013-04-11

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT01829568

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 4 locations

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Not Applicable

Conditions: Multiple Myeloma

Interventions: Biological: Galinpepimut-S
Biological: GM-CSF
Other: Montanide
Drug: lenalidomide
Drug: bortezomib

First Posted Date: 2013-04-09

Last Posted Date: 2020-01-10

Lead Sponsor: Sellas Life Sciences Group

Target Recruit Count: 22

Registration Number: NCT01827137

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-03-22

Last Posted Date: 2024-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 76

Registration Number: NCT01816971

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 2 locations

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2013-02-18

Last Posted Date: 2018-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 9

Registration Number: NCT01794039

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy